Aurinia Pharmaceuticals Aktie

13,29 EUR +0,32 EUR +2,43 %

11.05.2026

BMN

15,73 USD +0,51 USD +3,35 %

11.05.2026

BTT

Aurinia Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.1,66 Mrd. EUR

KGV7,70Div. Rendite0,00%

WKNA1W7D4

ISINCA05156V1022

SymbolAUPH

Aurinia Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

18.11.24BusinesswireAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

14.11.24BusinesswireAurinia to Participate in Jefferies London Healthcare Conference

07.11.24BusinesswireAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

WerbungAurinia Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

30.10.24BusinesswireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

24.09.24BusinesswireAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

13.09.24BusinesswireAurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

12.09.24BusinesswireAurinia Announces Board Restructuring

05.09.24BusinesswireAurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

28.08.24BusinesswireAurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

01.08.24BusinesswireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

19.07.24BusinesswireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

02.07.24BusinesswireAurinia to Participate in Upcoming Investor Healthcare Conferences

14.06.24BusinesswireAurinia Announces 2024 Annual General Meeting Results

05.06.24BusinesswireAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

04.06.24BusinesswireAurinia Addresses Dubious Proposals Put Forth by Lucien Selce

04.06.24BusinesswireAurinia Provides Update on Proxy Statement

30.05.24BusinesswireAurinia Will Attend 2024 Jefferies Global Healthcare Conference

14.05.24BusinesswireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024

09.05.24BusinesswireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

07.05.24BusinesswireAurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

02.05.24BusinesswireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

01.05.24BusinesswireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

30.04.24BusinesswireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

15.04.24BusinesswireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

09.04.24BusinesswireAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference

29.02.24BusinesswireAurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

27.02.24BusinesswireAurinia to Participate in Upcoming Investor Healthcare Conferences

15.02.24BusinesswireAurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

05.02.24BusinesswireAurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

05.01.24BusinesswireAurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

20.12.23BusinesswireAurinia Submits IND Application to US Food & Drug Administration for AUR 200

13.11.23BusinesswireAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

07.11.23BusinesswireAurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023

02.11.23BusinesswireAurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS? for Managing Lupus Nephritis

02.11.23BusinesswireAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

26.10.23BusinesswireAurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

19.10.23BusinesswireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

21.09.23BusinesswireAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

21.08.23BusinesswireAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

03.08.23BusinesswireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals News: auf dieser Seite finden Sie alle Aurinia Pharmaceuticals News und Nachrichten zur Aurinia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aurinia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aurinia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.